Ocnus.Net
News Before It's News
About us | Ocnus? |

Front Page 
 
 Africa
 
 Analyses
 
 Business
 
 Dark Side
 
 Defence & Arms
 
 Dysfunctions
 
 Editorial
 
 International
 
 Labour
 
 Light Side
 
 Research
Search

Research Last Updated: Jul 21, 2020 - 3:29:01 PM


Coronavirus drug from Synairgen hailed a game changer after trial found it cut need for intensive care
By Jamie Johnson, Telegraph, 20/7/20
Jul 20, 2020 - 4:47:10 PM

Email this article
 Printer friendly page

The treatment uses a protein called interferon beta which the body produces when it gets a viral infection

A coronavirus treatment drug has been hailed as a potential “game changer” after preliminary results of a clinical trial suggest it could dramatically reduce the number of patients needing intensive care.

Synairgen, a Southampton based company, has developed SNG001 - a drug which has been found to prevent Covid-19 coronavirus becoming more severe in around 79% of cases, it says.

The treatment uses a protein called interferon beta which the body produces when it gets a viral infection.

The protein is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune response.

The initial findings suggest the treatment cut the odds of a Covid-19 patient in hospital developing severe disease - such as requiring ventilation by 79 per cent.

Richard Marsden, CEO of Synairgen, said: "We are all delighted with the trial results announced today, which showed that SNG001 greatly reduced the number of hospitalised Covid-19 patients who progressed from ‘requiring oxygen’ to ‘requiring ventilation’.

“It also showed that patients who received SNG001 were at least twice as likely to recover to the point where their everyday activities were not compromised through having been infected by SARS-CoV-2.

“In addition, SNG001 has significantly reduced breathlessness, one of the main symptoms of severe Covid-19.

“This assessment of SNG001 in Covid-19 patients could signal a major breakthrough in the treatment of hospitalised Covid-19 patients.

“Our efforts are now focused onworking with the regulators and other key groups to progress this potential Covid-19 treatment as rapidly as possible."

The scientist in charge of the trial, Tom Wilkinson, says if the results are confirmed in larger studies the new treatment will be "a game changer".

The double-blind trial involved 101 volunteers who had been admitted for treatment at nine UK hospitals for Covid-19 infections.

The results have not been published in a peer-reviewed journal, nor has the full data been made available.


Source:Ocnus.net 2020

Top of Page

Research
Latest Headlines
The Atomic Bomb and the End of World War II
Space: Little Failure, Large Implications
The Jews of Switzerland
Siberia on Fire
Space: Jericho, Shavit And Ofek
Nature Inspired Sustainable Systems
New technique to capture carbon dioxide could greatly reduce power plant greenhouse gases
Amazon women warriors and revolutionary pants
The Forgotten History of the Jewish, Anti-Zionist Left
Argentina’s House of Horrors